Last reviewed · How we verify
SPARC1104 modified dose regimen I
SPARC1104 modified dose regimen I is a drug that targets the PD-1/PD-L1 pathway.
SPARC1104 modified dose regimen I is a drug that targets the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | SPARC1104 modified dose regimen I |
|---|---|
| Sponsor | Sun Pharma Advanced Research Company Limited |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PD-1/PD-L1 interaction, SPARC1104 modified dose regimen I is believed to enhance the body's immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Safety Study of SPARC1104 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: